Laboratories

ACCREDITED LABORATORIES

Laboratories that wish to perform the analysis of doping controls for sports under the World Anti-Doping Code must achieve and maintain accreditation from WADA.  The International Standard for Laboratories (ISL) and its related technical documents specify the criteria that must be met for accreditation and re-accreditation, as well as standards that must be met for the production of valid test results and evidentiary data.

APPROVED LABORATORIES

To fully serve the development of the Athlete Biological Passport (ABP), particularly in regions where the current network of WADA-accredited laboratories may be limited, WADA has approved these laboratories to conduct blood analyses in support of the ABP.

Technical Documents

WADA publishes, from time to time, specific technical requirements, addressing particular operational areas of the accredited laboratories, in a Technical Document.

The Technical Documents constitute level-2 elements of the World Anti-Doping Program, and therefore implementation of the technical recommendations described in them is mandatory and must occur by the effective date specified in the Technical Document.

Technical Documents supersede any previous publication on a similar topic, or if applicable, the International Standard for Laboratories (ISL). The document in effect is the Technical Document whose effective date most recently precedes that of sample receipt date by the laboratory.

Technical Documents In Effect

Technical Document
In force
(in alphabetical order)
Summary of modifications Effective Date*
TD2019BAR TD2019BAR  - Summary of modifications 1 June 2019
TD2019CG/LH TD2019CG/LH - Summary of modifications 1 Mar. 2019
TD2019DL Version 2 TD2019DL Version 2  - Summary of modifications 1 Sept.  2019
TD2018EAAS TD2018EAAS - Summary of modifications 1 Sep. 2018
TD2014EPO TD2014EPO - Summary of modifications 1 Sep. 2014
TD2019GH TD2019GH - Summary of modifications 15 May 2019
TD2015IDCR TD2015IDCR - Summary of modifications 1 Sep. 2015
TD2019IRMS TD2019IRMS - Summary of modifications 1 Mar. 2019
TD2009LCOC   1 Jan. 2009
TD2019LDOC   4 Nov. 2019
TD2019MRPL TD2019MRPL - Summary of modifications 15 May 2019
TD2019NA TD2019NA - Summary of modifications 1 Mar. 2019

TD2019APMU

  1 Mar. 2019

* Deadline for implementation

TECHNICAL LETTERS

WADA publishes Technical letters on an ad-hoc basis in order to provide instruction and guidance to the Laboratories, WADA-Approved Laboratories for the ABP and other stakeholders on particular issues related to the analysis, interpretation and reporting of results for specific Prohibited Substance(s) and/or Prohibited Method(s) or on the application of specific Laboratory procedures. Technical Letters are modified and/or withdrawn by WADA as deemed appropriate.

The Technical Letters constitute a WADA Laboratory standard document which supersedes any previous publication on a similar topic and becomes an integral part of the International Standard for Laboratories (ISL), and therefore the described technical recommendations are mandatory and shall be implemented as soon as possible after approval by the WADA Executive Committee and publishing on WADA’s website.

A Technical Letter shall be applied to samples which are received by the Laboratory on and after the Technical Letter’s effective date.

TECHNICAL LETTERS IN EFFECT

Title Document Number Version Number Effective Date
Meclofenoxate TL01 2.0 24 March 2006
Mebeverine Metabolism TL02 2.0 08 June 2012
Zilpaterol TL03 2.0 04 December 2014
Zeranol TL04 2.0 07 May 2015
Oxilofrine TL05 2.0 07 May 2015
Possible Metabolism of Proguanil into Chlorazanil TL06 2.0 27 January 2016
Andarine - Flutamide TL07 2.0 17 August 2016
Use of Internal Standards TL08 4.0 18 January 2017
Oxethazaine TL09 2.0 16 February 2017
In situ Formation of Exogenous Compounds TL10 2.0 12 April 2017
Oxymorphone TL11 2.0 21 December 2017
Ostarine TL12 2.0 31 January 2018
Trimetazidine TL13 2.0 31 January 2018
Difference in “A” and “B” Sample Urine Characteristics TL14 2.0 06 March 2018
Hydromorphone TL15 2.0 06 March 2018
Tretoquinol TL16 2.0 20 December 2018
Detection of Tulobuterol in the presence of Bupropion TL17 2.0 16 April 2019
Testolactone TL18 1.0 23 September 2019
Prednisone and Prednisolone TL19 2.0 23 September 2019
Specific substances with a steroid structure TL20 1.0 23 September 2019

In Situ Formation of 4-androstene-3,6,17-trione (6-oxo) and Metabolites

TL21

1.0

4 November 2019

GUIDELINES

WADA publishes guidelines relating to doping control activities.

In cooperation with WADA, the International Anti-Doping Agreement (IADA) has also developed guidelines for Anti-Doping Organizations that have already obtained an ISO certification or that wish to be ISO-certified. These are: Guidelines for Transition and Guidelines for Certification.

As with all guidelines under the World Anti-Doping Program, these documents are subject to ongoing review and reassessment.

WADA encourages feedback on the content of the Guidelines, and recommends that stakeholders always consult this Web site for the latest version.

Laboratory Guidelines currently in force:

LABORATORY TESTING FIGURES

In accordance with Article 14.5 of the World Anti-Doping Code (the Code), WADA, acting as a central clearinghouse for Doping Control data, annually publishes statistical reports as reported by the WADA accredited laboratories in the Anti-Doping Administration and Management System (ADAMS).

The latest WADA Anti-Doping Testing Figures Report can be accessed here

For a more complete overview of the Testing Figures, please consult the comprehensive Questions and Answers document.

LABORATORY ASSESSORS

Collaboration between WADA and the International Laboratory Accreditation Cooperation (ILAC) provides an important opportunity to conduct the International Standard for Laboratories (ISL) assessment concurrently with the ISO/IEC 17025 assessment for the WADA accredited anti-doping laboratories.

The List of ISL Assessors contains the names of the assessors from ILAC-member accreditation bodies trained by WADA for
the ISL assessment.